Injection of skin cells from the palm or sole into the stump site of amputees
Autologous Volar Fibroblast Injection Into the Stump Site of Amputees
This study is testing if injecting skin cells from the palm or sole into the stump of below-the-knee amputees can make the skin healthier and more comfortable.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Johns Hopkins University Academic / other |
| Locations | 1 site (Baltimore, Maryland) |
| Trial ID | NCT03947450 on ClinicalTrials.gov |
What this trial studies
This clinical trial tests the safety and efficacy of injecting volar fibroblasts, which are skin cells sourced from the palm or sole, into the stump site of individuals with below-the-knee amputations. The study aims to thicken the epidermal layer and improve skin firmness at the stump site, which is often prone to irritation and breakdown due to prosthetic use. Participants will be evaluated through questionnaires and non-invasive imaging to assess the effectiveness of the treatment. The trial will be conducted at Johns Hopkins University, focusing on optimizing injection techniques and monitoring outcomes related to skin health and quality of life.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 65 with below-the-knee amputations who have been using a prosthetic for at least three months.
Not a fit: Patients who do not have a below-the-knee amputation or those who are not using a prosthetic may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly improve skin integrity and comfort for amputees using prosthetics.
How similar studies have performed: Previous studies have shown that fibroblast injections can enhance skin characteristics, suggesting potential success for this approach in amputees.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients interested in study participation must meet all of the following inclusion criteria: * May be male or female * Must be between 18 years and 65 years of age * Must have a below the knee amputation. * Must be using a prosthetic for the vicinity of 3 months or have had osteo-integration of a prosthetic in place for 1 month. * In the opinion of the investigator, must be medically able to undergo the administration of study material determined by laboratory tests obtained within 7 days before baseline for which the investigator identified no clinically significant abnormality. * Be able to comprehend the informed consent document and provide consent for participation * Females of childbearing potential must: * have a negative pregnancy test at screening * agree to not become pregnant or breastfeed for the period of the study through 1 month after completion of the study * be willing to use a reliable form of contraception during the study * Be willing and able to comply with the scheduled visits, biopsy/injection procedures, wound care instructions treatment plan, and other study procedures for the duration of the study. Exclusion Criteria: Patients meeting any of the following criteria will be ineligible for study participation: * A skin erosion deeper than the skin dermis. * Having received any investigational drug within 30 days prior to study entry * An allergy history to any study materials including local anesthetic, dimethyl sulfoxide, human albumin, or bovine constituents, hetastarch, or EMLA (lidocaine 2.5% and prilocaine 2.5%). * Pregnant, lactating, or trying to become pregnant * A history of keloid formation * Having a significant medical history that the investigator feels is not safe for study participation (for example, some forms of autoimmune conditions, metastatic cancer, infectious diseases such as HIV, HTLV I/II, Hepatitis B, Hepatitis C). Biopsies taken from individuals with infections that are not allowed to enter the cell therapy core will make it such that these individuals cannot participate. * Specifically we will exclude those with autoimmune diseases affecting the skin such as lupus. * Presence of necrotic ischemic tissue on any stump ulcers, and/or capillary refill on stump skin of greater than 3 seconds * Active infection of the residual limb. * Active smoker during the study * We will also exclude those who are on chronic immunosuppressive therapies such as oral steroids, but also those on chronic topical steroids in the area of investigation. * Recent amputee who has not yet been approved to use a prosthetic. * Use of a prosthetic for less than 3 months. * Amputees with neuromas of the terminal limb within the last 3 months. * Known bleeding disorder. * For those receiving Bellafill/collagen skin test: history of serious allergy, such as anaphylaxis. * For whole stump injections: Have a history of congenital or idiopathic methemoglobinemia, glucose-6-phosphate deficiencies, or use of medications associated with drug-induced methemoglobinemia. (specifically: Sulfonamides, Acetaminophen, Acetanilid, Aniline dyes, Benzocaine, Chloroquine, Dapsone, Naphthalene, Nitrates and Nitrites, Nitrofurantoin, Nitroglycerin, Nitroprusside, Pamaquine, Para-aminosalicylic acid, Phenacetin, Phenobarbital, Phenytoin, Primaquine, or Quinine.)
Where this trial is running
Baltimore, Maryland
- Department of Dermatology at Johns Hopkins University — Baltimore, Maryland, United States (Recruiting)
Study contacts
- Principal investigator: Luis Garza, MD PhD — Johns Hopkins University
- Study coordinator: Ruizhi Wang, MPhil
- Email: rwang53@jhmi.edu
- Phone: 410-502-7546
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.